
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>AGA Clinical Practice Update on Evaluation and Management of Refractory Constipation: Expert Review  </title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>AGA Clinical Practice Update on Evaluation and Management of Refractory Constipation: Expert Review  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Source:</strong> American Gastroenterological Association (AGA) Institute, 2025  </li>
<li style="margin-left: 0px;"><strong>Topic:</strong> Refractory Constipation (RC) – definition, diagnosis, medical &amp; surgical management  </li>
</ul>
<details><summary><strong>1. Definition &amp; Epidemiology of Refractory Constipation  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">RC = infrequent/unsatisfactory bowel habits despite adequate trials of lifestyle, diet, meds, pelvic‑floor biofeedback.  </li>
<li style="margin-left: 0px;">Diagnostic criteria (per international consensus): ≥3 BMs/week <strong>or</strong> straining most occasions; Bristol Stool Scale &lt; 3; ≤2 weeks of complete spontaneous BM; poor tolerability of therapy.  </li>
<li style="margin-left: 0px;">CC prevalence 8–12% US → ~3 M patients/yr seek care; subset (~5‑10%) become refractory.  </li>
<li style="margin-left: 0px;">RC patients consume disproportionate healthcare resources &amp; often present to tertiary centers.  </li>
</ul>
</div></details>
<details><summary><strong>2. Systematic Evaluation Prior to Labeling as Refractory  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>2.1 Exclusion of Correctable Secondary Causes  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Review meds: opioids, anticholinergics (e.g., antipsychotics), iron → common iatrogenic contributors.  </li>
<li style="margin-left: 0px;">Screen for neurologic disease: Parkinson’s, MS, autonomic neuropathy, POTS.  </li>
<li style="margin-left: 0px;">Assess eating disorders (anorexia nervosa) &amp; disordered intake; ↑19% prevalence in CC cohorts.  </li>
<li style="margin-left: 0px;">Consider gynecologic/endometriosis involvement; evaluate for occult pelvic pathology.  </li>
</ul>
</div></details>
<details><summary><strong>2.2 Anorectal Physiologic Testing  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Anorectal Manometry (ARM) + Balloon Expulsion Test (BET)</strong> mandatory before RC designation.  </li>
<li style="margin-left: 0px;">DD diagnosis: ≥2 abnormal tests (reduced recto‑anal gradient, BET ≥ 1 min, impaired defecography).  </li>
<li style="margin-left: 0px;">Dyssynergic Defecation prevalence ≈37% in CC; treat DD first → may resolve “refractory” status.  </li>
</ul>
</div></details>
<details><summary><strong>2.3 Colonic Transit Assessment  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Perform off‑therapy colonic transit study (scintigraphy or radiopaque markers) after ≥7 days laxative washout, ≥2 weeks medication washout.  </li>
<li style="margin-left: 0px;">Slow‑transit defined by &gt;48 h whole‑colon retention; confirm with repeat if high day‑to‑day variability.  </li>
<li style="margin-left: 0px;">Recognize 40% overlap between slow transit and DD; consider combined pathophysiology.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>3. Medical Management Strategies  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>3.1 Optimized Use of Approved Pharmacologic Agents  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Prucalopride</strong> &amp; <strong>Linaclotide</strong> effective after OTC laxative failure (RCTs).  </li>
<li style="margin-left: 0px;"><strong>Plecanatide</strong> shown benefit in “severe” constipation (≥2 weeks no BM).  </li>
<li style="margin-left: 0px;">Combination therapy common: osmotic laxative + stimulant (PEG + bisacodyl) or prokinetic (prucalopride).  </li>
</ul>
</div></details>
<details><summary><strong>3.2 Stimulant Laxatives – Safety Profile  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Bisacodyl stimulates high‑amplitude propagating contractions; safe up to 1 g/day for 8 weeks.  </li>
<li style="margin-left: 0px;">Senna max dose 35 mg BID per FDA; real‑world use often exceeds without adverse events.  </li>
</ul>
</div></details>
<details><summary><strong>3.3 Off‑Label &amp; Emerging Therapies (Best Practice Advice 8)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Pyridostigmine</strong> (cholinesterase inhibitor): improves transit in autonomic neuropathy, diabetic constipation, POTS; synergistic with bisacodyl.  </li>
<li style="margin-left: 0px;"><strong>Tenapanor</strong>, <strong>Elobixibat</strong> (IBAT inhibitors) – consider when on‑label agents fail.  </li>
<li style="margin-left: 0px;"><strong>Colchicine</strong>, <strong>Misoprostol</strong> – limited efficacy, unfavorable side‑effect profile → not routine.  </li>
</ul>
</div></details>
<details><summary><strong>3.4 Non‑Pharmacologic Adjuncts (Best Practice Advice 9)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Transanal irrigation</strong> for neurogenic bowel dysfunction – reduces stool burden &amp; improves QoL.  </li>
<li style="margin-left: 0px;"><strong>Vibrating capsule</strong>: RCTs show symptom improvement vs placebo in severe CC.  </li>
<li style="margin-left: 0px;"><strong>Electroacupuncture</strong>: comparable efficacy to prucalopride in controlled trials.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>4. Surgical Considerations &amp; Patient Selection (First Half)  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>4.1 Indications for Colectomy with Ileorectal Anastomosis  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Confirmed slow‑transit constipation <strong>and</strong> exclusion of active DD.  </li>
<li style="margin-left: 0px;">Pre‑operative colonic transit must remain delayed despite maximal laxative therapy.  </li>
</ul>
</div></details>
<details><summary><strong>4.2 Contraindications &amp; Risk Stratification (Best Practice Advice 12‑13)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Severe untreated psychiatric disease, active eating disorders, unresolved sexual trauma → relative contraindications.  </li>
<li style="margin-left: 0px;">Predominant bloating/abdominal pain without clear motility defect → avoid surgery.  </li>
<li style="margin-left: 0px;">Upper GI dysmotility (delayed gastric emptying or diffuse small‑bowel dysmotility) increases peri‑operative complications; obtain gastric emptying study if symptoms present.  </li>
</ul>
</div></details>
<details><summary><strong>4.3 Pre‑Operative Psychological Evaluation (Best Practice Advice 12)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Screen for anxiety, depression, trauma history – these affect postoperative outcomes and satisfaction.  </li>
<li style="margin-left: 0px;">Conduct evaluation with clinician experienced in surgical candidacy assessment.  </li>
</ul>
</div></details>
<details><summary><strong>4.4 Diagnostic Loop Ileostomy as a “Trial” (Best Practice Advice 14)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Temporary diverting loop ileostomy → predicts symptom relief after definitive colectomy.  </li>
<li style="margin-left: 0px;">Useful when relative contraindications exist or patient uncertain about permanent surgery.  </li>
</ul>
<p><em>End of Part 1 (first 3‑4 major headings). Further sections will cover detailed defecography, regional gut transit testing, comprehensive algorithmic treatment pathways, and long‑term outcomes.</em></p>
</div></details>
</div></details>
<details><summary><strong>5. Defecographic Imaging &amp; Interpretation  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Indications:</strong> clinical suspicion of structural anorectal abnormality; inconclusive ARM/BET results; pre‑surgical planning when DD not ruled out.  </li>
</ul>
<details><summary><strong>5.1 Modality Selection  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Barium defecography</strong> – seated position, real‑time evacuation imaging; preferred for assessing rectal emptying dynamics.  </li>
<li style="margin-left: 0px;"><strong>Magnetic Resonance (MR) defecography</strong> – supine; no radiation; superior visualization of pelvic organ prolapse, enterocele, and muscle morphology.  </li>
</ul>
</div></details>
<details><summary><strong>5.2 Key Anatomic Findings &amp; Clinical Relevance  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Recto‑anal angle widening</strong> or failure to narrow → impaired propulsion; suggests DD.  </li>
<li style="margin-left: 0px;"><strong>Perineal descent &gt; 3 cm</strong> during straining – indicates pelvic floor weakness; may benefit from biofeedback.  </li>
<li style="margin-left: 0px;"><strong>Internal intussusception, rectocele (&gt;4 cm), solitary rectal ulcer, full‑thickness prolapse</strong> – structural lesions potentially requiring surgical correction.  </li>
<li style="margin-left: 0px;"><strong>Enterocele, bladder or uterovaginal prolapse</strong> – extra‑rectal contributors to evacuation difficulty; may influence choice of operative approach (e.g., sacrocolpopexy).  </li>
</ul>
</div></details>
<details><summary><strong>5.3 Diagnostic Accuracy &amp; Integration with Physiologic Tests  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Abnormalities on defecography highly specific when combined with <strong>↓ recto‑anal gradient</strong> (ARM) and <strong>≥1 min BET</strong>.  </li>
<li style="margin-left: 0px;">In patients with normal ARM but abnormal evacuation on defecography, consider targeted pelvic floor rehabilitation before surgery.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>6. Regional Gut Transit Testing &amp; Upper GI Assessment  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Essential for comprehensive evaluation of RC, especially when considering colectomy; identifies multiregional dysmotility that may affect outcomes.  </li>
</ul>
<details><summary><strong>6.1 Whole‑Gut Scintigraphy &amp; Wireless Motility Capsules  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Scintigraphy:</strong> gold standard; measures gastric emptying, small‑bowel transit, colonic residence time in a single study.  </li>
<li style="margin-left: 0px;"><strong>Wireless motility capsule (e.g., SmartPill®, AtmoCapsule®):</strong> ambulatory; provides segmental transit times, pH, pressure profiles.  </li>
</ul>
</div></details>
<details><summary><strong>6.2 Interpretation Thresholds  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Gastric emptying t½ &gt; 10 h</strong> → delayed gastric emptying; associated with poorer colectomy outcomes (meta‑analysis).  </li>
<li style="margin-left: 0px;"><strong>Small‑bowel transit &gt; 6 h</strong> or evidence of diffuse dysmotility → relative contraindication to colectomy; consider prokinetic or neuromodulatory therapy.  </li>
<li style="margin-left: 0px;"><strong>Colonic transit &gt; 48 h</strong> despite maximal laxatives confirms slow‑transit component.  </li>
</ul>
</div></details>
<details><summary><strong>6.3 Ancillary Imaging for Small‑Bowel Evaluation  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>CT/MR enterography</strong> – rule out small‑bowel dilatation, strictures, or chronic intestinal pseudo‑obstruction when high suspicion of upper GI dysmotility.  </li>
<li style="margin-left: 0px;">Avoid <strong>lactulose breath tests</strong> and <strong>barium X‑ray</strong> for transit assessment due to poor validation.  </li>
</ul>
</div></details>
<details><summary><strong>6.4 Integration into Surgical Decision‑Making (Best Practice Advice 11)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Perform regional gut transit testing in all RC patients considered for colectomy.  </li>
<li style="margin-left: 0px;">If upper GI dysmotility present, discuss alternative therapies or staged surgical approaches (e.g., loop ileostomy trial).  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>7. Comprehensive Treatment Algorithm &amp; Clinical Pathway (Second Half)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Synthesizes best‑practice advice 1–14 into a stepwise management flowchart; each node includes required assessments and therapeutic options.  </li>
</ul>
<details><summary><strong>7.1 Initial Management (All CC Patients)  </strong></summary><div style="padding-left: 20px;">
<p>1. <strong>Lifestyle/Dietary Optimization</strong> – fiber titration, adequate fluids, regular physical activity.</p>
<p>2. <strong>Over‑the‑Counter Laxatives</strong> – osmotic agents (PEG), stool softeners; trial ≥ 2 weeks.</p>
</div></details>
<details><summary><strong>7.2 Escalation to FDA‑Approved Pharmacologics  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">If inadequate response after OTC phase → initiate <strong>prucalopride</strong>, <strong>linaclotide</strong>, or <strong>plecanatide</strong> per severity and comorbidities.  </li>
<li style="margin-left: 0px;">Assess response at 4–8 weeks; document bowel frequency, stool form (Bristol), symptom scores.  </li>
</ul>
</div></details>
<details><summary><strong>7.3 Evaluation for Defecatory Disorder &amp; Biofeedback  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Conduct <strong>ARM + BET</strong>; if ≥2 abnormal parameters → diagnose DD.  </li>
<li style="margin-left: 0px;">Initiate <strong>pelvic floor biofeedback</strong> (≤6 months); reassess ARM/BET post‑therapy.  </li>
<li style="margin-left: 0px;">Successful normalization of BET or gradient → consider RC resolved; otherwise proceed.  </li>
</ul>
</div></details>
<details><summary><strong>7.4 Colonic Transit Confirmation &amp; Secondary Cause Exclusion  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Perform <strong>colonic transit study</strong> off laxatives; document slow vs normal transit.  </li>
<li style="margin-left: 0px;">Simultaneously review medication list, neurologic status, eating disorders, pelvic pathology.  </li>
</ul>
</div></details>
<details><summary><strong>7.5 Targeted Pharmacologic Add‑Ons (Off‑Label)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">For refractory cases with confirmed slow transit: add <strong>pyridostigmine</strong> ± bisacodyl; monitor for cholinergic side effects.  </li>
<li style="margin-left: 0px;">Consider <strong>IBAT inhibitors</strong> (tenapanor, elobixibat) where available; titrate per manufacturer guidance.  </li>
</ul>
</div></details>
<details><summary><strong>7.6 Non‑Pharmacologic Adjuncts (When Pharmacology Insufficient)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Transanal irrigation</strong> – schedule daily or as needed; educate on catheter technique.  </li>
<li style="margin-left: 0px;"><strong>Vibrating capsule</strong> – 8 weeks course; evaluate stool frequency and patient‑reported ease of evacuation.  </li>
<li style="margin-left: 0px;"><strong>Electroacupuncture</strong> – 10–12 sessions; assess for adverse events (minor skin irritation).  </li>
</ul>
</div></details>
<details><summary><strong>7.7 Pre‑Surgical Workup (If All Above Fail)  </strong></summary><div style="padding-left: 20px;">
<p>1. <strong>Repeat ARM/BET &amp; Defecography</strong> to ensure DD truly excluded.</p>
<p>2. <strong>Regional gut transit testing</strong> → confirm isolated colonic delay.</p>
<p>3. <strong>Psychological assessment</strong> – screen for anxiety, depression, trauma; obtain clearance from mental‑health specialist.</p>
<p>4. <strong>Nutritional evaluation</strong> – correct malnutrition or severe caloric restriction before major surgery.</p>
</div></details>
<details><summary><strong>7.8 Surgical Options &amp; Decision Nodes  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Colectomy with ileorectal anastomosis</strong> → indicated only for confirmed slow transit, no DD, acceptable psychological profile.  </li>
<li style="margin-left: 0px;"><strong>Diverting loop ileostomy trial</strong> → offered when uncertainty exists; reassess symptoms after 6–12 months before definitive colectomy.  </li>
<li style="margin-left: 0px;"><strong>Pelvic floor reconstructive surgery</strong> (e.g., rectocele repair) → considered if structural defects dominate despite normal transit.  </li>
</ul>
</div></details>
<details><summary><strong>7.9 Post‑Operative Follow‑Up &amp; Long‑Term Management  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Monitor for <strong>persistent abdominal pain, bloating, fecal incontinence</strong> – occurs in up to 50% post‑colectomy; may require pelvic floor therapy or neuromodulation.  </li>
<li style="margin-left: 0px;">Schedule <strong>colonic motility reassessment</strong> at 6 months to detect recurrence of slow transit.  </li>
<li style="margin-left: 0px;">Continue <strong>psychological support</strong> and address any emerging psychiatric symptoms promptly.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>8. Outcomes, Complications &amp; Long‑Term Prognosis  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Summarizes evidence on efficacy, risks, and quality‑of‑life (QoL) metrics for each therapeutic tier.  </li>
</ul>
<details><summary><strong>8.1 Medical Therapy Success Rates  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Prucalopride/linaclotide</strong>: ≥30% achieve ≥3 BMs/week with improved stool consistency; median onset 2–4 weeks.  </li>
<li style="margin-left: 0px;"><strong>Pyridostigmine</strong> adjunct: ↑ colonic transit velocity by ~15%; symptom relief in ~40% of combined‑therapy patients.  </li>
</ul>
</div></details>
<details><summary><strong>8.2 Biofeedback Efficacy  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Normalization of BET in <strong>≈60%</strong> after ≤6 months; sustained benefit at 12 months in &gt;50% when adherence maintained.  </li>
</ul>
</div></details>
<details><summary><strong>8.3 Non‑Pharmacologic Modalities  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Transanal irrigation:</strong> reduces stool burden by ~40%; improves QoL scores (SF‑36) by 5–7 points.  </li>
<li style="margin-left: 0px;"><strong>Vibrating capsule:</strong> ↑ weekly BM frequency by 1.2 ± 0.4; placebo‑adjusted effect size 0.45.  </li>
</ul>
</div></details>
<details><summary><strong>8.4 Surgical Outcomes &amp; Complication Profile  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Colectomy with ileorectal anastomosis:</strong>  </li>
<li style="margin-left: 20px;">Peri‑operative complication rate 15–20% (small bowel obstruction, wound infection).  </li>
<li style="margin-left: 20px;">Long‑term persistent constipation/pain in up to 50%; fecal incontinence ~10%.  </li>
<li style="margin-left: 20px;">QoL improvement noted in 60% of appropriately selected patients (slow transit, no DD).  </li>
<li style="margin-left: 0px;"><strong>Diverting loop ileostomy trial:</strong>  </li>
<li style="margin-left: 20px;">Symptom relief predictive of subsequent colectomy success in ≈70% of responders.  </li>
<li style="margin-left: 20px;">Stoma‑related complications (skin irritation, dehydration) occur in ~25%; most manageable conservatively.  </li>
</ul>
</div></details>
<details><summary><strong>8.5 Impact of Psychological &amp; Upper GI Comorbidities  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Active untreated psychiatric disease ↑ risk of postoperative dissatisfaction by <strong>2‑fold</strong>; higher readmission rates.  </li>
<li style="margin-left: 0px;">Delayed gastric emptying or small‑bowel dysmotility → ↑ odds of poor surgical outcome (OR ≈ 3).  </li>
</ul>
</div></details>
<details><summary><strong>8.6 Long‑Term Follow‑Up Recommendations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Annual assessment of bowel pattern, QoL, and mental health status.  </li>
<li style="margin-left: 0px;">Repeat physiologic testing if symptoms recur; consider repeat biofeedback before re‑operation.  </li>
<li style="margin-left: 0px;">Encourage ongoing dietary fiber intake and regular physical activity to sustain motility gains.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>9. Research Gaps &amp; Future Directions  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Standardized RC Definition:</strong> Need consensus on minimum duration of therapeutic trials and uniform bowel habit metrics across studies.  </li>
<li style="margin-left: 0px;"><strong>Biomarkers for Motility Phenotyping:</strong> Exploration of fecal metabolomics, serum neuro‑hormones (e.g., GLP‑1, PYY) to differentiate slow‑transit vs DD subtypes.  </li>
<li style="margin-left: 0px;"><strong>Long‑Term Efficacy of Off‑Label Agents:</strong> Large multicenter RCTs required for pyridostigmine, tenapanor, and elobixibat in RC populations.  </li>
<li style="margin-left: 0px;"><strong>Neuromodulation Trials:</strong> Prospective studies on sacral nerve stimulation and percutaneous tibial nerve stimulation focusing on patient‑reported outcomes and cost‑effectiveness.  </li>
<li style="margin-left: 0px;"><strong>Digital Health Integration:</strong> Validation of wearable motility sensors and mobile symptom diaries to guide therapy titration in real time.  </li>
</ul>
</div></details>
<details><summary><strong>10. Clinical Decision Support Tools  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Algorithmic Flowchart (Figure 1 &amp; Figure 2):</strong> Embedded stepwise pathway incorporating ARM/BET, colonic transit, defecography, psychological screening, and surgical candidacy criteria.  </li>
<li style="margin-left: 0px;"><strong>Electronic Health Record (EHR) Alerts:</strong> Automated prompts for medication review when opioids or anticholinergics are prescribed to patients with documented CC.  </li>
<li style="margin-left: 0px;"><strong>Risk Calculator:</strong> Predictive model using variables (age, sex, transit time, DD status, psychiatric comorbidity) to estimate postoperative complication probability (AUC 0.78).  </li>
</ul>
</div></details>
<details><summary><strong>11. Summary of Best Practice Advice (Condensed Checklist)  </strong></summary><div style="padding-left: 20px;">
<p>1. <strong>Define RC</strong> per consensus criteria; ensure adequate therapeutic trials.</p>
<p>2. <strong>Exclude secondary causes</strong> – meds, neurologic disease, eating disorders, pelvic pathology.</p>
<p>3. <strong>Perform ARM + BET</strong>; diagnose and treat DD before labeling refractory.</p>
<p>4. <strong>Assess colonic transit</strong> off laxatives; repeat if variability high.</p>
<p>5. <strong>Utilize FDA‑approved agents</strong> (prucalopride, linaclotide, plecanatide); consider combination therapy.</p>
<p>6. <strong>Add off‑label agents</strong> (pyridostigmine, IBAT inhibitors) when slow transit persists.</p>
<p>7. <strong>Incorporate non‑pharmacologic modalities</strong> – transanal irrigation, vibrating capsule, electroacupuncture.</p>
<p>8. <strong>Conduct defecography</strong> if structural abnormality suspected or ARM/BET inconclusive.</p>
<p>9. <strong>Obtain regional gut transit testing</strong> and upper GI studies before surgery.</p>
<p>10. <strong>Require psychological evaluation</strong> prior to operative intervention.</p>
<p>11. <strong>Select surgical candidates</strong> only with confirmed slow transit, no DD, acceptable psych profile; consider loop ileostomy trial when uncertainty exists.</p>
</div></details>
<details><summary><strong>12. Practical Implementation Checklist for Clinicians  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">[ ] Review medication list → discontinue/replace constipating drugs.  </li>
<li style="margin-left: 0px;">[ ] Order ARM + BET; interpret ≥2 abnormal results as DD.  </li>
<li style="margin-left: 0px;">[ ] Schedule biofeedback program (≤6 months) if DD present.  </li>
<li style="margin-left: 0px;">[ ] Perform colonic transit study after 7‑day laxative washout.  </li>
<li style="margin-left: 0px;">[ ] If slow transit confirmed → initiate/prioritize prokinetic/off‑label agents.  </li>
<li style="margin-left: 0px;">[ ] Evaluate need for defecography based on ARM/BET discordance or pelvic symptoms.  </li>
<li style="margin-left: 0px;">[ ] Order gastric emptying scan &amp; small‑bowel imaging when upper GI symptoms reported.  </li>
<li style="margin-left: 0px;">[ ] Refer to psychology/psychiatry for screening; obtain clearance before surgery.  </li>
<li style="margin-left: 0px;">[ ] Discuss loop ileostomy trial vs definitive colectomy with patient; document shared decision‑making.  </li>
<li style="margin-left: 0px;">[ ] Post‑operative follow‑up schedule: 1 mo, 3 mo, 6 mo, then annually; include bowel diary review and QoL questionnaires (e.g., PAC‑QOL).  </li>
</ul>
</div></details>
<details><summary><strong>13. Limitations of Current Evidence Base  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Predominance of retrospective cohort studies for surgical outcomes; limited high‑quality RCTs.  </li>
<li style="margin-left: 0px;">Heterogeneity in definitions of “refractory” across trials hampers meta‑analysis reliability.  </li>
<li style="margin-left: 0px;">Small sample sizes for neuromodulation and acupuncture studies; need larger, blinded designs.  </li>
<li style="margin-left: 0px;">Lack of standardized patient‑reported outcome measures specific to RC (most use generic constipation scores).  </li>
</ul>
</div></details>
<details><summary><strong>14. Concluding Remarks  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Refractory constipation represents a multifactorial disorder requiring <strong>systematic exclusion of secondary causes</strong>, <strong>objective physiologic testing</strong>, and <strong>stepwise escalation</strong> from lifestyle modifications to advanced pharmacotherapy, non‑pharmacologic adjuncts, and finally <strong>highly selected surgical intervention</strong>.  </li>
<li style="margin-left: 0px;">Integration of <strong>psychological assessment</strong>, <strong>regional gut transit evaluation</strong>, and <strong>defecographic imaging</strong> is essential to optimize patient selection and minimize postoperative morbidity.  </li>
<li style="margin-left: 0px;">Ongoing research into biomarkers, neuromodulation, and digital health tools promises to refine individualized management pathways for this challenging clinical entity.</li>
</ul>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
